Literature DB >> 21240484

Suppression of T-cell responses by tumor metabolites.

Katrin Singer1, Eva Gottfried, Marina Kreutz, Andreas Mackensen.   

Abstract

Tumor cells have developed multiple mechanisms to escape T-cell-mediated immune recognition. Recent work has revealed that the altered tumor metabolism depletes essential nutrients or leads to the accumulation of immunosuppressive metabolites in the tumor microenvironment. In this review, we discuss the suppressive activity of some metabolic key players, which are upregulated in human tumor cells, including indolamine-2,3-dioxygenase (IDO), arginase, inducible nitric oxide synthetase (iNOS), and lactate dehydrogenase (LDH)-A, on the adaptive immune system. A better understanding of the impact of metabolic alterations of tumor cells on effector T-cell functions could lead to new therapeutic strategies to improve the efficacy of cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21240484     DOI: 10.1007/s00262-010-0967-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

Review 1.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 2.  Tumor-infiltrating regulatory T cells: origins and features.

Authors:  Guoping Deng
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05

Review 3.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

4.  Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Authors:  John Stagg; Fabrice Andre; Sherene Loi
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 5.  The interplay between metabolic remodeling and immune regulation in glioblastoma.

Authors:  Pravin Kesarwani; Shiva Kant; Antony Prabhu; Prakash Chinnaiyan
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

6.  Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Authors:  Chantal G Lemay; Julia L Rintoul; Agnieszka Kus; Jennifer M Paterson; Vanessa Garcia; Theresa J Falls; Lisa Ferreira; Byram W Bridle; David P Conrad; Vera A Tang; Jean-Simon Diallo; Rozanne Arulanandam; Fabrice Le Boeuf; Kenneth Garson; Barbara C Vanderhyden; David F Stojdl; Brian D Lichty; Harold L Atkins; Kelley A Parato; John C Bell; Rebecca C Auer
Journal:  Mol Ther       Date:  2012-07-03       Impact factor: 11.454

7.  The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.

Authors:  M Cavia-Saiz; P Muñiz Rodríguez; B Llorente Ayala; M García-González; M J Coma-Del Corral; C García Girón
Journal:  Mol Biol Rep       Date:  2014-01-17       Impact factor: 2.316

8.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

9.  Lactate levels with glioblastoma multiforme.

Authors:  Arunpreet Singh Kahlon; Mariam Alexander; Arundeep Kahlon; Jonathan Wright
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-07

10.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.

Authors:  John Stagg; Bertrand Allard
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.